Process for the preparation of intermediates of trandolapril and use thereof for the preparation of trandolapril
A process for the preparation of an intermediate of trandolapril, (2S,3aR,7aS)-perhydroindole-2-carboxylic acid of Formula II is provided. Also provided are processes for preparing trandolapril.
1 . A process for the preparation of an intermediate of trandolapril, (2S,3aR,7aS)-perhydroindole-2-carboxylic acid of Formula II:
the process comprising:
(a) esterifying (3aR,7aS)-perhydroindole-2-carboxylic acid of Formula III:
with an alcohol of the formula ROH wherein R is an aliphatic, aryl or aralkyl group and a suitable acid to provide an acid addition salt of the compound of Formula IV:
wherein R has the aforestated meanings;
(b) reacting the acid addition salt of the compound of Formula IV with a first base to provide a compound of Formula V:
(c) reacting the compound of Formula IV with dibenzoyl-L-tartaric acid or di-p-toluoyl-L-tartaric acid and at least one alcohol of the formula R 1 OH wherein R 1 is an alkyl group containing from 1 to about 12 carbon atoms, and adding a second base to precipitate a compound of Formula VI:
(d) hydrolyzing the compound of Formula VI to provide the compound of Formula II.
2 . The process of claim 1 , wherein the alcohol of the formula ROH is selected from the group consisting of a linear or branched C 1 -C 30 aliphatic alcohol, C 6 -C 30 aryl alcohol, C 6 -C 30 araalkyl alcohol and mixtures thereof.
3 . The process of claim 1 , wherein the alcohol of the formula ROH is selected from the group consisting of methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol, butyl alcohol, benzyl alcohol and mixtures thereof
4 . The process of claim 1 , wherein the suitable acid is a sulfonic acid.
5 . The process of claim 4 , wherein the sulfonic acid is p-toluenesulfonic acid.
6 . The process of claim 1 , wherein the suitable acid is a hydrochloric acid.
7 . The process of claim 1 , wherein step (a) is carried out in a solvent.
8 . The process of claim 7 , wherein the solvent is selected from the group consisting of an aromatic hydrocarbon, aliphatic hydrocarbons, halogenated aliphatic hydrocarbon, ether, nitrile and mixtures thereof.
9 . The process of claim 7 , wherein the solvent is selected from the group consisting n-hexane, benzene, toluene, o-, m-, and p-xylene (single or mixed isomers), ethylbenzene and mixtures thereof.
10 . The process of claim 1 , wherein the first base is an amine selected from the group consisting of a primary amine, secondary amine, tertiary amine, aliphatic amine, aromatic amine and mixtures thereof.
11 . The process of claim 1 , wherein the first base is one or more tertiary amines.
12 . The process of claim 1 , wherein the first base is selected from the group consisting of triethylamine, ammonia and mixtures thereof.
13 . The process of claim 1 , wherein the lower aliphatic alcohol of step (c) is selected from the group consisting of methanol, ethanol, butanol, propanol, isopropyl alcohol and mixtures thereof.
14 . The process of claim 1 , wherein in step (c) the compound of Formula IV is reacted with dibenzoyl-L-tartaric acid.
15 . The process of claim 1 , comprising:
(a) esterifying (3aR,7aS)-perhydroindole-2-carboxylic acid of Formula III:
with benzyl alcohol and a suitable acid selected from the group consisting of p-toluenesulfonic acid and hydrochloric acid to provide an acid addition salt thereof;
(b) reacting the acid addition salt with a trialkylamine:
(c) reacting the product of step (b) with dibenzoyl-L-tartaric acid and at least one lower aliphatic alcohol of the formula R 1 OH wherein R 1 is an alkyl group containing from 1 to about 6 carbon atoms, and adding a second base to precipitate a compound of Formula VI; and
(d) hydrolyzing the compound of Formula VI to provide the compound of Formula II.
16 . The process of claim 1 , and thereafter converting the compound of Formula II to trandolapril or a pharmaceutically acceptable salt thereof.
17 . The process of claim 15 , and thereafter converting the compound of Formula II to trandolapril or a pharmaceutically acceptable salt thereof.
18 . A process for the preparation of trandolapril comprising:
(a) reacting N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine and N,N′-carbonyldiimidazole in the presence of a solvent to form an N-carboxyanhydride; and
(b) reacting the N-carboxyanhydride with (2S,3aR,7aS)-perhydroindole-2-carboxylic acid to provide trandolapril.
19 . The process of claim 18 , wherein the solvent is selected from the group consisting of a halogenated hydrocarbon solvent, ether solvent, amide solvent and mixtures thereof.
20 . The process of claim 18 , wherein the solvent is one or more halogenated hydrocarbon solvents.
21 . The process of claim 20 , wherein the halogenated hydrocarbon solvent is selected from the group consisting of dichloromethane, dichloroethane and mixtures thereof.
22 . The process of claim 18 , wherein the solvent is selected from the group consisting of dichloromethane, dichloroethane, tetrahydrofuran, dimethylformamide and mixtures thereof.
23 . A process for preparing trandolapril comprising reacting a N-[(S)-1-carbethoxybutyl]-(S)-alanyl halide of Formula X:
Me
wherein X is a halide and Ph is phenyl with (2S,3aR,7aS)-perhydroindole-2-carboxylic acid of Formula II:
in the presence of a base to provide trandolapril.
24 . The process of claim 23 , wherein the base is an organic base selected from the group consisting of a dialkylamine, trialkylamine, heterocyclic amine and mixtures thereof.
25 . The process of claim 23 , wherein the base is selected from the group consisting of imidazole, triethyl amine, diethylamine, pyridine, n-methyl morpholine and mixtures thereof.
26 . The process of claim 23 , wherein the reaction takes place in one or more organic solvents.
27 . The process of claim 26 , wherein the one or more organic solvents is an anhydrous solvent.
28 . The process of claim 27 , wherein the one or more anhydrous solvents is selected from the group consisting of a chlorinated hydrocarbon, aromatic hydrocarbon, aliphatic hydrocarbon and mixtures thereof.
29 . The process of claim 26 , wherein the organic solvent is selected from the group consisting of dichloromethane, dichloroethane and mixtures thereof.
30 . The process of claim 28 , wherein the organic solvent is selected from the group consisting of benzene, toluene, and mixtures thereof.
31 . The process of claim 28 , wherein the organic solvent is selected from the group consisting of hexane, heptane, cyclopentane, cyclohexane and mixtures thereof.
32 . The process of claim 23 , wherein the N-[(S)-1-carbethoxybutyl]-(S)-alanyl halide of Formula X is formed by reacting N-[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanine with a halogenating agent in a suitable anhydrous solvent and in the presence or absence of an inert gas.
33 . The process of claim 23 , wherein the trandolapril is thereafter converted to a pharmaceutically acceptable salt thereof.
34 . The process of claim 23 , further comprising the step of adjusting the pH to about 4 to about 5.
35 . The process of claim 23 , further comprising the step of purifying trandolapril.
36 . Trandolapril prepared in accordance with the process of claim 23 having a purity of greater than about 95%.
37 . A process for preparing trandolapril comprising reacting (2S,3aR,7aS)-perhydroindole-2-carboxylic acid of Formula II:
with a trialkyl or aryl silyl halide in the presence of a first base and in situ reacted with a N-[(S)-1-carbethoxybutyl]-(S)-alanyl halide of Formula X:
wherein X is a halide and Ph is phenyl in an organic solvent and in the presence of a second base followed by treatment with a suitable acid to obtain trandolapril.
38 . The process of claim 37 , wherein the second base is an organic base selected from the group consisting of a dialkylamine, trialkylamine, heterocyclic amine and mixtures thereof.
39 . The process of claim 37 , wherein the second base is selected from the group consisting of imidazole, triethylamine, diethylamine, pyridine, n-methyl morpholine and mixtures thereof.